Bristol-Myers Squibb (NYSE:BMY) Rating Lowered to "Buy" at Wall Street Zen

Wall Street Zen downgraded shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) from a strong-buy rating to a buy rating in a research report report published on Friday morning.

A number of other equities research analysts also recently weighed in on BMY. Jefferies Financial Group lowered their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Finally, Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Up 1.2%

Shares of BMY traded up $0.58 during midday trading on Friday, hitting $48.42. The company had a trading volume of 9,231,487 shares, compared to its average volume of 13,060,030. The company's 50 day moving average price is $49.34 and its 200 day moving average price is $55.06. The stock has a market cap of $98.54 billion, a price-to-earnings ratio of -10.95, a PEG ratio of 2.07 and a beta of 0.38. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company's revenue was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($4.40) EPS. On average, equities research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The stock was bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.09% of the company's stock.

Institutional Trading of Bristol-Myers Squibb

A number of institutional investors have recently made changes to their positions in the stock. LaFleur & Godfrey LLC lifted its stake in Bristol-Myers Squibb by 3.5% during the fourth quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company's stock valued at $2,463,000 after purchasing an additional 1,487 shares during the last quarter. Brighton Jones LLC lifted its stake in Bristol-Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Tyche Wealth Partners LLC lifted its stake in Bristol-Myers Squibb by 20.6% during the fourth quarter. Tyche Wealth Partners LLC now owns 5,729 shares of the biopharmaceutical company's stock valued at $324,000 after purchasing an additional 979 shares during the last quarter. Silver Oak Securities Incorporated lifted its stake in Bristol-Myers Squibb by 76.4% during the fourth quarter. Silver Oak Securities Incorporated now owns 6,997 shares of the biopharmaceutical company's stock valued at $392,000 after purchasing an additional 3,030 shares during the last quarter. Finally, Telos Capital Management Inc. lifted its stake in Bristol-Myers Squibb by 3.7% during the fourth quarter. Telos Capital Management Inc. now owns 110,412 shares of the biopharmaceutical company's stock valued at $6,245,000 after purchasing an additional 3,985 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.